Abstract
Background:
Cardiovascular disease is the major cause of mortality between patients go through hemodialysis. Carvedilol, an unselective beta-blocker with alpha-blocking properties, has shown promise in improvement of cardiovascular results in this high-risk population.
Objective:
To demonstrate the effects of carvedilol on cardiovascular events and all-cause mortality rate in patients go through maintenance hemodialysis.
Methods:
A systematic study and meta-analysis was held by searching databases including PubMed, Embase, Cochrane Library, and Scopus up to May 2024. Studies involved randomized controlled trials and group studies evaluating carvedilol’s impact on cardiovascular events or mortality rate in adult hemodialysis patients. Risk ratios and hazard ratios were pooled using random-effects models.
Results:
Nine studies involving 2,136 hemodialysis patients were included. Carvedilol use was frequently linked with reduced cardiovascular mortality (HR 0.69; 96% CI 0.55–0.87) and all-cause mortality rate (HR 0.75; 96% CI 0.61–0.91). Carvedilol also remarkably lowered the incidence of heart failure-related hospitalizations (RR 0.73; 96% CI 0.56–0.96).
Conclusion:
Carvedilol evaluates a beneficial effect in reducing cardio-vascular and all-cause mortality in hemodialysis patients, with potential advantages in managing heart failure. Further large-scale RCTs are justified to confirm these findings.
Keywords: cardiovascular, mortality and morbidity, hospitalization